WO2024214044 - MULTICOMPONENT COMPLEXES, INCLUDING SALTS AND HYDRATES AND SOLVATES, OF INUPADENANT
National phase entry is expected:
Publication Number
WO/2024/214044
Publication Date
17.10.2024
International Application No.
PCT/IB2024/053562
International Filing Date
11.04.2024
Title **
[English]
MULTICOMPONENT COMPLEXES, INCLUDING SALTS AND HYDRATES AND SOLVATES, OF INUPADENANT
[French]
COMPLEXES MULTICOMPOSANTS COMPRENANT DES SELS, DES HYDRATES ET DES SOLVATES D'INUPADENANT
Applicants **
ITEOS BELGIUM SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
Inventors
REECE, Hayley Ann
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
BOULTON, Katharine
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
VAN BERKEL, Chantalle
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
ARET, Edwin
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
ROSS, Sally
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
GANGOLLI, Esha
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
SRIVASTAVA, Shouraydeep
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
LAGER, Joanne
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
MADASAMY, Pratheepan
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
ROSSETTI, Maura
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
MARTINOLI, Chiara
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
NAP, Wilhelmina
c/o iTeos Belgium SA
Rue des Frères Wright 29
B-6041 Gosselies, BE
Priority Data
63/458,761
12.04.2023
US
63/458,840
12.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 13414 | |
| EPO | Filing, Examination | 254138 | |
| Japan | Filing | 530 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 108635 |
Total: 377324 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to multicomponent complexes, such as salt forms of inupadenant, and hydrates and solvates thereof, formed by the combination of inupadenant and a coformer, such as an acid. In some embodiments, the present disclosure relates to crystalline and amorphous salts of inupadenant, and hydrates and solvates thereof. In some embodiments, the present disclosure relates to pharmaceutically acceptable salts of inupadenant, and hydrates and solvates thereof. In some embodiments, the present disclosure relates to inorganic salts of inupadenant, and hydrates and solvates thereof. In some embodiments, the present disclosure relates to organic salts of inupadenant, and hydrates and solvates thereof. In some embodiments, the present disclosure relates to compositions, dosage forms, kits, methods, and uses relating to multicomponent complexes of inupadenant, and hydrates and solvates thereof.[French]
La présente divulgation concerne des complexes multicomposants, tels que des formes salines d'inupadenant, et des hydrates et des solvates de ceux-ci, formés par la combinaison d'inupadenant et d'un co-formeur, tel qu'un acide. Dans certains modes de réalisation, la présente divulgation concerne des sels cristallins et amorphes d'inupadenant, et des hydrates et des solvates de ceux-ci. Dans certains modes de réalisation, la présente divulgation concerne des sels pharmaceutiquement acceptables d'inupadenant, et des hydrates et des solvates de ceux-ci. Dans certains modes de réalisation, la présente divulgation concerne des sels inorganiques d'inupadenant, et des hydrates et des solvates de ceux-ci. Dans certains modes de réalisation, la présente divulgation concerne des sels organiques d'inupadenant, et des hydrates et des solvates de ceux-ci. Dans certains modes de réalisation, la présente divulgation concerne des compositions, des formes posologiques, des kits, des procédés et des utilisations se rapportant à des complexes multicomposants d'inupadenant, et des hydrates et des solvates de ceux-ci.